A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

• Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
• Body mass index (BMI) ≥18.0 and ≤32.0 kg/m^2
• Able to swallow multiple tablets

Exclusion criteria

The main exclusion criteria include but are not limited to the following:

• History or presence of any of the following:

• Adrenal insufficiency
• Hepatic or renal impairment
• Gallstones, hepatitis disease, or hepatic porphyrias
• Psychosis
• Clinically significant hypotension, cardiac arrhythmia, cardiac conduction abnormalities, or recurrent unexplained syncopal events
• Second- or third-degree atrioventricular heart block
• Clinically significant sick sinus syndrome
• Recurrent seizures, increased risk for seizures, or myasthenia gravis
• Clinically significant hematologic disorders/blood dyscrasias, including adverse hematologic reactions to any drugs or experimental therapies
• Any systemic fungal infection
• Chronic infection
• Glaucoma
• Hypothyroidism
• Unexplained electrolyte abnormalities, current hyponatremia, diuretic use, or syndrome of inappropriate antidiuretic hormone secretion (siADH)
• Severe dermatologic reaction
• Stomach ulcer
• Has a first-degree relative with multiple unexplained syncopal events, unexplained cardiac arrest, or sudden cardiac death, or has a known family history of an inherited arrhythmia syndrome (including Brugada syndrome)
• History of cancer (malignancy)
• Unable to refrain from or anticipates the use of: Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing